Collegium Pharmaceutical, Inc.
NASDAQ:COLLDrug Manufacturers - Specialty & Generic
-$0.24 today
- Market cap
- $805.79M
- Beta
- 0.75
- P/E (TTM)
- 14.3
- EPS (TTM)
- $2.34
Volume 0.49M
Average 0.50M
COLL Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Collegium Pharmaceutical, Inc.NASDAQ: COLL
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $193.52M rose 8.9% year over year, behind the +19.9% change in trailing-twelve-month revenue. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at +18.9% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $831.96M (+6.6%) for the fiscal year ending Dec 2026, a slowdown from the +23.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $193.52M-5.8% QoQ
- Last fiscal yearDec 2025
- $780.57M+23.6% YoY
- LTMMar 2026
- $796.33M+19.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.9% | +6.2% | -2.7 pp |
| 1 year | +23.6% | +6.6% | -17.0 pp |
| 3-year CAGR | +18.9% | +3.3% | -15.6 pp |
| 5-year CAGR | +4.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 780.57M USD
- Year-over-year change
- +23.6%
- 4-year CAGR
- +29.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 780.57M | +23.6% |
| FY2024 | 2024-12-31 | 631.45M | +11.4% |
| FY2023 | 2023-12-31 | 566.77M | +22.2% |
| FY2022 | 2022-12-31 | 463.93M | +67.6% |
| FY2021 | 2021-12-31 | 276.87M | — |
Revenue vs competitors
How COLL compares with its peers on the latest reported figures
- COLL's LTM Mar 2026 revenue of $796.33M is the highest of the 3 companies compared; the peer median is $384.36M.
- Its year-over-year change of +19.9% is the highest of 3, against a peer median of -14.3%.
- Over three fiscal years its annual growth of +18.9% compares with a peer median of -2.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $796.33M | +19.9% | +18.9% | |
| LTM Mar 2026 | $734.86M | +4.6% | +2.9% | |
| LTM Mar 2026 | $33.86M | -33.2% | -7.3% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — |
| Peer median (excluding COLL) | $384.36M | -14.3% | -2.2% | |
Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 276.87M | 463.93M | 566.77M | 631.45M | 780.57M |
| Cost of Revenue | 126.25M | 254.45M | 240.6M | 254.11M | 317.31M |
| Gross Profit | 150.62M | 209.49M | 326.17M | 377.34M | 463.26M |
| Gross Margin | 54.4% | 45.2% | 57.5% | 59.8% | 59.3% |
| Research & Development | 9.45M | 3.98M | 0 | 0 | 0 |
| Selling, General & Admin | 118.96M | 172.19M | 159.21M | 182.98M | 276.17M |
| Operating Expenses | 132.99M | 176.17M | 159.21M | 207.45M | 276.17M |
| Depreciation & Amortization | 68.92M | 138.94M | 149.26M | 169.16M | 226.07M |
| EBITDA | 86.56M | 173.31M | 308.33M | 341.7M | 401.01M |
| EBITDA Margin | 31.3% | 37.4% | 54.4% | 54.1% | 51.4% |
| Operating Income | 17.63M | 33.32M | 166.96M | 169.9M | 187.08M |
| Operating Margin | 6.4% | 7.2% | 29.5% | 26.9% | 24.0% |
| Interest Income | 12K | 1.05M | 15.62M | 13.98M | 11.29M |
| Interest Expense | 21.01M | 63.21M | 83.34M | 73.97M | 82.31M |
| Other Income / Expenses | (21M) | (62.17M) | (91.23M) | (71.33M) | (94.47M) |
| Income Before Tax | (3.37M) | (28.85M) | 75.73M | 98.57M | 92.62M |
| Pre-Tax Margin | -1.2% | -6.2% | 13.4% | 15.6% | 11.9% |
| Income Tax Expense | (74.89M) | (3.85M) | 27.58M | 29.38M | 29.75M |
| Net Income | 71.52M | (25M) | 48.16M | 69.19M | 62.87M |
| Net Margin | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
| EPS (Basic) | 2.05 | (0.74) | 1.60 | 2.14 | 1.98 |
| EPS (Diluted) | 1.86 | (0.74) | 1.29 | 1.86 | 1.73 |
| Weighted Avg Shares | 34.94M | 33.83M | 33.74M | 32.27M | 31.71M |
| Weighted Avg Shares (Diluted) | 41.05M | 33.83M | 41.79M | 40.42M | 39.7M |
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
Intrinsic Alpha fair value
Locked
Current Price
$25.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.